Section Arrow
Quote
AARD.NASDAQ
- Aardvark Therapeutics Inc
Quotes are at least 15-min delayed:2025/02/13 14:43 EST
Last
 13.3
-- (--)
Day High 
15.18 
Prev. Close
-- 
1-M High
-- 
Volume 
1.23M 
Bid
13.25
Ask
13.45
Day Low
11.55 
Open
15.18 
1-M Low
-- 
Market Cap 
-- 
Currency USD 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.65/--
Enterprise Value
--
Balance Sheet
Book Value Per Share
N/A
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc0.075-0.0162-17.76%0PE
EDSAEdesa Biotech3.285+1.425+76.61%-- 
MBRXMoleculin Biotech1.78+1.36+323.81%-- 
OCEAOcean Biomedical0.1524-0.0214-12.31%-- 
RXRXRecursion Pharmaceuticals8.3688+0.0288+0.35%-- 
Quotes are at least 15-min delayed：2025/02/13 14:43 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which haveinitiated a Phase 3 clinical trial for hyperphagia associated with PWS.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.